PTHLH and hypercalcemia disease: Further investigating the biomolecular mechanisms driving hypercalcemia in gynecologic malignancies may allow us to better appreciate associated morbidity and targeted treatment options in gynecologic and non-gynecologic malignancies involving dysregulated PTHrP expression and subsequent hypercalcemia.